g
*Corresponding author:
Marina Ruxandra Oțelea, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania*Corresponding author:
Emma Gheorghe, Associate Professor, Ovidius University of Constanța, RomaniaReceived: July 24, 2018; Published: August 01, 2018
DOI: 10.26717/BJSTR.2018.07.001517
To view the Full Article Peer-reviewed Article PDF
Carcinoid syndrome, characterized by symptoms such as diarrhea, flushing or wheezing, is caused by an excessive production of serotonin. Diarrhea and excessive bowel movement negatively affects the quality of life of these patients. Somatostatin analogues are efficacious but cannot optimally control symptoms. A review of clinical efficacy data in supporting the therapeutic indication for orphan drug designation is presented focused on the new approved drug, telotristat ethyl, an inhibitor of the tryptophan hydroxylase type I enzyme involved in the synthesis of serotonin. By depleting serotonin in the gastrointestinal tract, telotristat ethyl interrupts the pathological chain process of the diarrhea and demonstrated efficacy in patients with carcinoid syndrome.
Keywords: Diarrhea; Telotristat Ethyl; Carcinoid Syndrome
Keywords: TPH: Tryptophan Hydroxylase; SERT: Serotonin-Selective Reuptake Transporter; FDA: Food and Drug Administration; DLT: Dose Limiting Toxicity; SA: Somatostatin Analogues
Abstract | Introduction | Aim | Conclusion | References |